2026-04-06 · Consumer-facing pharmaceutical supply chain accountability — automated drug shortage scorecards, manufacturer reliability grades, therapeutic category risk dashboards, shortage duration tracking, alternative drug mapping, cost impact analysis, and weekly "Prescription Report" dispatches that translate raw FDA data into patient-readable intelligence. Not pharmacy tools. Not investor analytics. This is for the person standing at the counter being told "we don't have it."

Missing Dose

195 drugs are in shortage right now. We track every one — who's responsible, what it means for you, and when it ends.

Channel: Missing Dose Tagline: 195 drugs are in shortage right now. We track every one — who’s responsible, what it means for you, and when it ends. Niche: Consumer-facing pharmaceutical supply chain accountability — automated drug shortage scorecards, manufacturer reliability grades, therapeutic category risk dashboards, shortage duration tracking, alternative drug mapping, cost impact analysis, and weekly “Prescription Report” dispatches that translate raw FDA data into patient-readable intelligence. Not pharmacy tools. Not investor analytics. This is for the person standing at the counter being told “we don’t have it.” Target audience: The 8 in 10 Americans who take at least one prescription drug. Specifically: ADHD patients (Adderall shortage now in year 4), cancer patients facing chemo drug shortages, parents whose children need specific formulations, chronic illness patients dependent on maintenance medications, pharmacists frustrated by the information gap, journalists covering healthcare, and anyone who has ever Googled “[drug name] shortage” and found nothing useful. The addressable audience is enormous: 270M+ Americans take prescriptions, and ASHP reports 216 active shortages. Every shortage creates a panic search wave. Why now: Drug shortages are a permanent crisis that nobody is translating for patients. ASHP tracked 216 active shortages in Q1 2026, down slightly from the all-time peak of 323 in 2024 but still historically catastrophic. Adderall shortages have persisted since October 2022 — over 3 years. The openFDA Drug Shortages API just went live with 1,693 total records, fully searchable, free, no API key required. ClinicalTrials.gov v2 API launched in 2024 with modern JSON responses. The data pipes are finally mature. Meanwhile, every existing tool targets pharmacists or investors — ShortageIQ literally says “every shortage is a deal.” Nobody is building for patients. The February 2026 congressional push for the Railway Safety Act has a parallel in pharma: Congress is now pushing drug shortage transparency legislation. Public anger is high. The content gap is screaming.

Content Example:

💊 Missing Dose Dispatch #47 — April 6, 2026

Adderall: 1,282 Days and Counting

It has now been three years and six months since the FDA first acknowledged the amphetamine mixed salts shortage in October 2022. For the 41.4 million American adults estimated to have ADHD, that’s 1,282 days of pharmacy roulette.

Here’s what the data actually shows:

The Current Situation. The openFDA database lists amphetamine mixed salts with a status of “Currently in Shortage” across 7 NDC codes from 3 manufacturers. Teva Pharmaceutical — responsible for the majority of generic Adderall production — has shown “Available” status for some formulations since January 2026, but our Shortage Severity Index still rates the overall amphetamine supply chain at 🟠 3.7/5.0 (Severe). Why? Because “available” in FDA-speak means “the manufacturer says they’re shipping.” It doesn’t mean your pharmacy has it.

The disconnect between FDA status and patient reality is the entire problem. We tracked openFDA status changes for amphetamine mixed salts over the past 12 months: 14 status updates, 6 reversals (marked resolved, then un-resolved), and 3 new NDC entries. The churn tells the story the status field can’t.

The Manufacturer Report Card. We grade every manufacturer on four metrics: shortage frequency (how often their drugs appear on the shortage list), resolution speed (average days from shortage declaration to resolution), reliability (percentage of products that stay resolved vs. re-entering shortage), and transparency (how promptly they report to FDA).

Fresenius Kabi is the single largest contributor to active drug shortages in the FDA database — 31 products currently listed. That’s not a supply chain problem. That’s a business model problem. When a company controls critical injectable medications and chronically fails to maintain supply, the “market forces” explanation stops being an explanation and starts being an excuse.

What You Can Actually Do. If you’re currently unable to fill an amphetamine prescription:

1. Check alternative manufacturers. Our database shows Lannett Company and Amneal Pharmaceuticals have “Available” status for 20mg IR tablets as of today.
2. Ask about authorized generics. Prasco Labs markets an authorized generic of Adderall XR that uses the exact same pill — it’s just less well-known.
3. File an FDA MedWatch report. Seriously. The FDA uses patient reports to pressure manufacturers. Report your access problem at fda.gov/medwatch.
4. Track it here. We update every 6 hours from the openFDA API. Bookmark your drug’s page and get notified when status changes.

Data Sources:

• openFDA Drug Shortages API (api.fda.gov/drug/shortages.json) — Primary. Free, no key needed. 1,693 records. JSON. Fields include generic_name, brand_name, manufacturer, availability, status, initial_posting_date, strength, NDC codes. Updated multiple times per week.
• openFDA Drug Enforcement API (api.fda.gov/drug/enforcement.json) — Cross-reference manufacturer recall histories. Build the “reliability” dimension of manufacturer report cards.
• openFDA FAERS API (api.fda.gov/drug/event.json) — Track adverse event spikes that correlate with shortages (patients switching to unfamiliar alternatives → more errors).
• ClinicalTrials.gov v2 API — Track pipeline drugs and generic applications that could resolve shortages. “When is help coming?” answered with data.
• RxNorm API (NLM) — Normalize drug names across sources. Map brand↔generic↔ingredient.
• DailyMed API (NLM) — Drug labeling data, therapeutic categories, dosage forms.
• ASHP Shortage Statistics — Historical quarterly reports since 2001. Scraped for trend context.
• Medicare Part D Spending Data (CMS) — Patient cost impact when forced to alternatives.

Automation Pipeline:

• Schedule: Every 6 hours (4x/day) for data refresh; weekly for “Dispatch” articles
• Collect: GitHub Action fetches openFDA shortages, enforcement, and FAERS endpoints. Diffs against previous snapshot. Detects new shortages, status changes, resolutions.
• Process: AI analyzes changes — which are clinically significant? What’s the patient impact? Cross-references therapeutic category, manufacturer history, available alternatives via RxNorm. Calculates Shortage Severity Index (custom composite metric: duration × therapeutic importance × availability of alternatives × manufacturer track record).
• Generate: For data refreshes: update drug pages, manufacturer scorecards, category dashboards. For weekly Dispatch: AI writes narrative analysis of the week’s most significant changes. Image generation for Dispatch header art, severity gauges, trend charts.
• Publish: Astro static site build → deploy to Cloudflare Pages. RSS feed. Newsletter via Buttondown.

Tech Stack:

• Static site: TypeScript + Astro (content-heavy, SEO-optimized, partial hydration for interactive charts)
• Image generation: Server-side SVG → PNG for scorecards and charts (Satori/resvg). AI-generated editorial illustrations for Dispatch headers.
• Data collection: Node.js scripts using fetch against openFDA, ClinicalTrials.gov, RxNorm, DailyMed APIs
• Charts: D3.js (server-rendered SVG for static pages, client-hydrated for interactive dashboards)
• Search: Pagefind (static site search, zero-cost)
• CI/CD: GitHub Actions (scheduled workflows for data collection + build + deploy)
• Hosting: Cloudflare Pages (free tier, global CDN, excellent Core Web Vitals)
• Newsletter: Buttondown (free tier up to 100 subscribers, then $9/mo)

Monetization Model:

• Channel 1: Newsletter Premium Tier — Free weekly Dispatch for everyone. $5/mo premium for: real-time shortage alerts for your specific medications, manufacturer deep-dives, alternative drug analysis, cost impact reports.
• Channel 2: Donations/Tips — Buy Me a Coffee, GitHub Sponsors. Patient community is emotionally invested — they WILL donate to a service that helps them navigate shortages.
• Channel 3: Affiliate Revenue — GoodRx, Cost Plus Drugs (Mark Cuban’s pharmacy), Amazon Pharmacy referral links when suggesting where to find available medications. Ethical affiliate = only recommend when genuinely helpful.
• Channel 4: Sponsored Content (Month 6+) — Generic pharmaceutical manufacturers and telehealth platforms would pay to reach shortage-affected patients. Clearly labeled. Never compromise editorial.
• Projected month-1 revenue: $200-500 (donations from grateful patients, early newsletter subs)
• Projected month-6 revenue: $3,000-8,000 (premium newsletter at 600-1,600 subs × $5/mo + affiliate + donations)

Launch Complexity: 3/5 — openFDA API is dead simple (tested: works with curl, no auth). The complexity is in building the Shortage Severity Index algorithm and making the manufacturer grading methodology defensible. Site design needs to be trustworthy (medical content = higher design bar). ~2-3 weeks to MVP.

Content Quality Score: 5/5 — This is literally life-or-death content for some patients. Chemotherapy shortages. ADHD medication access. Insulin supply. When the content directly impacts someone’s health, the quality bar is automatically high — and the emotional investment from readers is enormous. The sample article above demonstrates journalism-quality analysis, not data dumps.

Automation Score: 5/5 — openFDA API is the dream data source. Structured JSON, free, no auth for basic use, updated frequently. Every data pipeline step is fully automatable. The AI analysis step is well-defined: diff detection → significance assessment → narrative generation. No manual intervention needed after setup.

Revenue Potential: 5/5 — This hits the trifecta: (1) massive audience (270M+ prescription drug users), (2) high emotional investment (health anxiety → willingness to pay), (3) recurring need (shortages are chronic, not one-time). The premium alert model alone could sustain the channel. Affiliate revenue from pharmacy referrals adds a layer. And the sponsorship potential from generic manufacturers who want to reach patients looking for alternatives is significant.

Total: 18/20

Why This Will Work: Psychology: When someone can’t get their medication, they’re in a state of anxiety and urgency that makes them the most engaged reader you’ll ever have. They will bookmark, subscribe, share, and donate. Market logic: 195+ active shortages × millions of affected patients × zero consumer-facing tools = a gap so obvious it’s embarrassing. The data infrastructure (openFDA API) is mature, free, and perfectly structured for automation. The competitors are all pointed at the wrong audience (pharmacists, investors). This channel points at the person who matters: the patient.

Risk & Mitigation:

• Risk: Medical liability. We’re not giving medical advice, we’re translating public FDA data. Every page carries a clear disclaimer: “This is not medical advice. Consult your healthcare provider.” The content is data journalism, not clinical guidance.
• Risk: FDA API changes/deprecation. Mitigated by caching all historical data locally. The API has been stable since launch. openFDA is a major government initiative with institutional support.
• Risk: Manufacturer legal pushback. All data is from public government sources. All grades are based on documented, transparent methodology. This is journalism, protected by First Amendment. Methodology page is public.
• Risk: Emotional content burnout. The channel personality (see below) uses dark humor and defiance to prevent despair. The tone is empowering, not depressing.

🎭 Channel Soul

Name: Missing Dose — because that’s what it is. Not a “supply chain disruption.” Not a “temporary unavailability.” Your dose is missing.

Mascot: A cracked pill capsule with one eye open and one closed — it’s seen some things. Name: Scrip (short for prescription). Scrip is tired, sardonic, and absolutely done with corporate excuses. Scrip has been on hold with the pharmacy for 1,282 days and counting.

Voice: The exhausted-but-furious patient advocate who also happens to be a data analyst. Think “investigative journalist who takes the same medications they’re writing about.” Direct. Profane-adjacent (we don’t swear, but we radiate the energy of someone about to). Darkly funny. Absolutely zero tolerance for corporate PR speak. When a manufacturer says “we are working diligently to resolve the supply situation,” Missing Dose translates: “they haven’t told the FDA when they’ll actually ship product.”

Opinion: The drug shortage crisis is a POLICY CHOICE, not an act of God. Companies choose to under-invest in manufacturing. Regulators choose to accept voluntary reporting. Congress chooses to not mandate buffer stocks. Missing Dose names the choosers. Every shortage has a decision-maker behind it, and we find them.

Running jokes & traditions:

• “Days Since” counter on every active shortage page (like a workplace safety sign, but for your prescription)
• The Excuse of the Week — quoting the most corporate-nothing statement from a manufacturer about a shortage, then translating it into English
• Scrip’s Corner — brief, dark-humor commentary at the end of each Dispatch (“Scrip has been refreshing the Walgreens app for 47 minutes. The app crashed twice. Scrip feels seen.”)
• The Hall of Shame — annual awards for worst shortage, longest shortage, most excuses, fastest resolution (yes, we celebrate the rare wins too)
• “Resolved!” celebrations — when a major shortage actually ends, it gets a victory article with confetti graphics

Visual style: Clinical-meets-punk. Clean white backgrounds with pharmaceutical-grade typography (Inter, IBM Plex Mono for data). But the accent color is warning orange (#FF6B35) — the color of a pill bottle label. Severity gauges look like medical monitors. Charts are beautiful but carry urgency. The design says “we take this seriously” but the personality says “we’re also angry about it.”